eCD4-Ig variants that more potently neutralize HIV-1

Journal of Virology

Volumn 92, Issue 12, 2018, Pages

  Fetzer, Ina ^a   Gardner, Matthew R ^a   Davis Gardner, Meredith E ^a   Prasad, Neha R ^a   Alfant, Barnett ^a   Weber, Jesse A ^a   Farzan, Michael ^a  

^a SCRIPPS RESEARCH INSTITUTE   (United States)

Author keywords

CD4; CD4 Ig; Coreceptor; ECD4 Ig; Human immunodeficiency virus

Indexed keywords

GLYCOPROTEIN GP 120; HUMAN IMMUNODEFICIENCY VIRUS FUSION INHIBITOR; HUMAN IMMUNODEFICIENCY VIRUS FUSION INHIBITOR ECD4 IG; UNCLASSIFIED DRUG; CD4 ANTIGEN; CD4 IMMUNOGLOBULIN; FUSION PROTEIN; HUMAN IMMUNODEFICIENCY VIRUS ANTIBODY; IMMUNOLOGIC FACTOR; NEUTRALIZING ANTIBODY;

ANTIBODY DEPENDENT CELLULAR CYTOTOXICITY; ANTIBODY PRODUCTION; ANTIVIRAL ACTIVITY; ARTICLE; CONTROLLED STUDY; DRUG EFFICACY; DRUG POTENCY; DRUG STABILITY; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; PHOTON CORRELATION SPECTROSCOPY; PLASMID; PRIORITY JOURNAL; PROTEIN CONFORMATION; PROTEIN DOMAIN; VIRUS ENTRY; VIRUS ISOLATION; VIRUS NEUTRALIZATION; VIRUS SHEDDING; VIRUS STRAIN; ANIMAL; CD4+ T LYMPHOCYTE; CELL LINE; DOG; GENETICS; HEK293 CELL LINE; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNOLOGY;

ANIMALS; ANTIBODIES, NEUTRALIZING; ANTIBODY-DEPENDENT CELL CYTOTOXICITY; CD4 ANTIGENS; CD4 IMMUNOADHESINS; CD4-POSITIVE T-LYMPHOCYTES; CELL LINE; DOGS; HEK293 CELLS; HIV ANTIBODIES; HIV ENVELOPE PROTEIN GP120; HIV INFECTIONS; HIV-1; HUMANS; IMMUNOLOGIC FACTORS; RECOMBINANT FUSION PROTEINS;

EID: 85047668360     PISSN: 0022538X     EISSN: 10985514     Source Type: Journal    
DOI: 10.1128/JVI.02011-17     Document Type: Article

References (53)

1. Checkley MA, Luttge BG, Freed EO. 2011. HIV-1 envelope glycoprotein biosynthesis, trafficking, and incorporation. J Mol Biol 410:582-608. https://doi.org/10.1016/j.jmb.2011.04.042
2. Wilen CB, Tilton JC, Doms RW. 2012. HIV: cell binding and entry. Cold Spring Harb Perspect Med 2:a006866. https://doi.org/10.1101/cshperspect .a006866
3. Liu J, Bartesaghi A, Borgnia MJ, Sapiro G, Subramaniam S. 2008. Molecular architecture of native HIV-1 gp120 trimers. Nature 455:109-113. https://doi.org/10.1038/nature07159
4. Choe H, Farzan M, Sun Y, Sullivan N, Rollins B, Ponath PD, Wu L, Mackay CR, LaRosa G, Newman W, Gerard N, Gerard C, Sodroski J. 1996. The beta-chemokine receptors CCR3 and CCR5 facilitate infection by primary HIV-1 isolates. Cell 85:1135-1148. https://doi.org/10.1016/S0092-8674(00) 81313-6
5. Feng Y, Broder CC, Kennedy PE, Berger EA. 1996. HIV-1 entry cofactor: functional cDNA cloning of a seven-transmembrane, G protein-coupled receptor. Science 272:872-877. https://doi.org/10.1126/science.272.5263 .872
6. Diskin R, Scheid JF, Marcovecchio PM, West AP, Jr, Klein F, Gao H, Gnanapragasam PN, Abadir A, Seaman MS, Nussenzweig MC, Bjorkman PJ. 2011. Increasing the potency and breadth of an HIV antibody by using structure-based rational design. Science 334:1289-1293. https:// doi.org/10.1126/science.1213782
7. Huang J, Ofek G, Laub L, Louder MK, Doria-Rose NA, Longo NS, Imamichi H, Bailer RT, Chakrabarti B, Sharma SK, Alam SM, Wang T, Yang Y, Zhang B, Migueles SA, Wyatt R, Haynes BF, Kwong PD, Mascola JR, Connors M. 2012. Broad and potent neutralization of HIV-1 by a gp41-specific human antibody. Nature 491:406-412. https://doi.org/10.1038/nature11544
8. Walker LM, Huber M, Doores KJ, Falkowska E, Pejchal R, Julien JP, Wang SK, Ramos A, Chan-Hui PY, Moyle M, Mitcham JL, Hammond PW, Olsen OA, Phung P, Fling S, Wong CH, Phogat S, Wrin T, Simek MD, Koff WC, Wilson IA, Burton DR, Poignard P. 2011. Broad neutralization coverage of HIV by multiple highly potent antibodies. Nature 477:466-470. https:// doi.org/10.1038/nature10373
9. Scheid JF, Mouquet H, Ueberheide B, Diskin R, Klein F, Oliveira TY, Pietzsch J, Fenyo D, Abadir A, Velinzon K, Hurley A, Myung S, Boulad F, Poignard P, Burton DR, Pereyra F, Ho DD, Walker BD, Seaman MS, Bjorkman PJ, Chait BT, Nussenzweig MC. 2011. Sequence and structural convergence of broad and potent HIV antibodies that mimic CD4 binding. Science 333:1633-1637. https://doi.org/10.1126/science.1207227
10. West AP, Jr, Scharf L, Scheid JF, Klein F, Bjorkman PJ, Nussenzweig MC. 2014. Structural insights on the role of antibodies in HIV-1 vaccine and therapy. Cell 156:633-648. https://doi.org/10.1016/j.cell.2014.01.052
11. Mascola JR, Haynes BF. 2013. HIV-1 neutralizing antibodies: understanding nature's pathways. Immunol Rev 254:225-244. https://doi.org/10 .1111/imr.12075
12. Mouquet H, Scharf L, Euler Z, Liu Y, Eden C, Scheid JF, Halper-Stromberg A, Gnanapragasam PN, Spencer DI, Seaman MS, Schuitemaker H, Feizi T, Nussenzweig MC, Bjorkman PJ. 2012. Complex-type N-glycan recognition by potent broadly neutralizing HIV antibodies. Proc Natl Acad Sci U S A 109:E3268-E3277. https://doi.org/10.1073/pnas.1217207109
13. Huang J, Kang BH, Ishida E, Zhou T, Griesman T, Sheng Z, Wu F, Doria-Rose NA, Zhang B, McKee K, O'Dell S, Chuang GY, Druz A, Georgiev IS, Schramm CA, Zheng A, Joyce MG, Asokan M, Ransier A, Darko S, Migueles SA, Bailer RT, Louder MK, Alam SM, Parks R, Kelsoe G, Von Holle T, Haynes BF, Douek DC, Hirsch V, Seaman MS, Shapiro L, Mascola JR, Kwong PD, Connors M. 2016. Identification of a CD4-binding-site antibody to HIV that evolved near-pan neutralization breadth. Immunity 45:1108-1121. https://doi.org/10.1016/j.immuni.2016.10.027
14. Berger CT, Alter G. 2011. Natural killer cells in spontaneous control of HIV infection. Curr Opin HIV AIDS 6:208-213. https://doi.org/10.1097/COH .0b013e3283457798
15. Bonsignori M, Pollara J, Moody MA, Alpert MD, Chen X, Hwang KK, Gilbert PB, Huang Y, Gurley TC, Kozink DM, Marshall DJ, Whitesides JF, Tsao CY, Kaewkungwal J, Nitayaphan S, Pitisuttithum P, Rerks-Ngarm S, Kim JH, Michael NL, Tomaras GD, Montefiori DC, Lewis GK, DeVico A, Evans DT, Ferrari G, Liao HX, Haynes BF. 2012. Antibody-dependent cellular cytotoxicity-mediating antibodies from an HIV-1 vaccine efficacy trial target multiple epitopes and preferentially use the VH1 gene family. J Virol 86:11521-11532. https://doi.org/10.1128/JVI.01023-12
16. Scully E, Alter G. 2016. NK cells in HIV disease. Curr HIV/AIDS Rep 13:85-94. https://doi.org/10.1007/s11904-016-0310-3
17. Wei X, Decker JM, Wang S, Hui H, Kappes JC, Wu X, Salazar-Gonzalez JF, Salazar MG, Kilby JM, Saag MS, Komarova NL, Nowak MA, Hahn BH, Kwong PD, Shaw GM. 2003. Antibody neutralization and escape by HIV-1. Nature 422:307-312. https://doi.org/10.1038/nature01470
18. Gardner MR, Farzan M. 2017. Engineering antibody-like inhibitors to prevent and treat HIV-1 infection. Curr Opin HIV AIDS 12:294-301. https://doi.org/10.1097/COH.0000000000000367
19. Gardner MR, Kattenhorn LM, Kondur HR, von Schaewen M, Dorfman T, Chiang JJ, Haworth KG, Decker JM, Alpert MD, Bailey CC, Neale ES, Jr, Fellinger CH, Joshi VR, Fuchs SP, Martinez-Navio JM, Quinlan BD, Yao AY, Mouquet H, Gorman J, Zhang B, Poignard P, Nussenzweig MC, Burton DR, Kwong PD, Piatak M, Jr, Lifson JD, Gao G, Desrosiers RC, Evans DT, Hahn BH, Ploss A, Cannon PM, Seaman MS, Farzan M. 2015. AAVexpressed eCD4-Ig provides durable protection from multiple SHIV challenges. Nature 519:87-91. https://doi.org/10.1038/nature14264
20. Chiang JJ, Gardner MR, Quinlan BD, Dorfman T, Choe H, Farzan M. 2012. Enhanced recognition and neutralization of HIV-1 by antibody-derived CCR5-mimetic peptide variants. J Virol 86:12417-12421. https://doi.org/ 10.1128/JVI.00967-12
21. Dorfman T, Moore MJ, Guth AC, Choe H, Farzan M. 2006. A tyrosinesulfated peptide derived from the heavy-chain CDR3 region of an HIV-1-neutralizing antibody binds gp120 and inhibits HIV-1 infection. J Biol Chem 281:28529-28535. https://doi.org/10.1074/jbc.M602732200
22. Kwong JA, Dorfman T, Quinlan BD, Chiang JJ, Ahmed AA, Choe H, Farzan M. 2011. A tyrosine-sulfated CCR5-mimetic peptide promotes conformational transitions in the HIV-1 envelope glycoprotein. J Virol 85: 7563-7571. https://doi.org/10.1128/JVI.00630-11
23. Chen W, Feng Y, Prabakaran P, Ying T, Wang Y, Sun J, Macedo CD, Zhu Z, He Y, Polonis VR, Dimitrov DS. 2014. Exceptionally potent and broadly cross-reactive, bispecific multivalent HIV-1 inhibitors based on single human CD4 and antibody domains. J Virol 88:1125-1139. https://doi .org/10.1128/JVI.02566-13
24. Wu H, Kwong PD, Hendrickson WA. 1997. Dimeric association and segmental variability in the structure of human CD4. Nature 387: 527-530. https://doi.org/10.1038/387527a0
25. Ryu SE, Kwong PD, Truneh A, Porter TG, Arthos J, Rosenberg M, Dai XP, Xuong NH, Axel R, Sweet RW, Hendrickson WA. 1990. Crystal structure of an HIV-binding recombinant fragment of human CD4. Nature 348: 419-426. https://doi.org/10.1038/348419a0
26. Wang JH, Yan YW, Garrett TP, Liu JH, Rodgers DW, Garlick RL, Tarr GE, Husain Y, Reinherz EL, Harrison SC. 1990. Atomic structure of a fragment of human CD4 containing two immunoglobulin-like domains. Nature 348:411-418. https://doi.org/10.1038/348411a0
27. Wang JH, Meijers R, Xiong Y, Liu JH, Sakihama T, Zhang R, Joachimiak A, Reinherz EL. 2001. Crystal structure of the human CD4 N-terminal twodomain fragment complexed to a class II MHC molecule. Proc Natl Acad Sci U S A 98:10799-10804. https://doi.org/10.1073/pnas.191124098
28. Arthos J, Deen KC, Chaikin MA, Fornwald JA, Sathe G, Sattentau QJ, Clapham PR, Weiss RA, McDougal JS, Pietropaolo C, Axel R, Truneh A, Maddon PJ, Sweet RW. 1989. Identification of the residues in human CD4 critical for the binding of HIV. Cell 57:469-481. https://doi.org/10.1016/ 0092-8674(89)90922-7
29. Chen W, Feng Y, Gong R, Zhu Z, Wang Y, Zhao Q, Dimitrov DS. 2011. Engineered single human CD4 domains as potent HIV-1 inhibitors and components of vaccine immunogens. J Virol 85:9395-9405. https://doi .org/10.1128/JVI.05119-11
30. Traunecker A, Luke W, Karjalainen K. 1988. Soluble CD4 molecules neutralize human immunodeficiency virus type 1. Nature 331:84-86. https://doi.org/10.1038/331084a0
31. Allaway GP, Davis-Bruno KL, Beaudry GA, Garcia EB, Wong EL, Ryder AM, Hasel KW, Gauduin MC, Koup RA, McDougal JS, Maddon PJ. 1995. Expression and characterization of CD4-IgG2, a novel heterotetramer that neutralizes primary HIV type 1 isolates. AIDS Res Hum Retroviruses 11:533-539. https://doi.org/10.1089/aid.1995.11.533
32. Arthos J, Cicala C, Steenbeke TD, Chun TW, Dela Cruz C, Hanback DB, Khazanie P, Nam D, Schuck P, Selig SM, Van Ryk D, Chaikin MA, Fauci AS. 2002. Biochemical and biological characterization of a dodecameric CD4-Ig fusion protein: implications for therapeutic and vaccine strategies. J Biol Chem 277:11456-11464. https://doi.org/10.1074/jbc.M111191200
33. Pang Y, Song H, Kim JH, Hou X, Cheng W. 2014. Optical trapping of individual human immunodeficiency viruses in culture fluid reveals heterogeneity with single-molecule resolution. Nat Nanotechnol 9:624-630. https://doi.org/10.1038/nnano.2014.140
34. Wagh K, Bhattacharya T, Williamson C, Robles A, Bayne M, Garrity J, Rist M, Rademeyer C, Yoon H, Lapedes A, Gao H, Greene K, Louder MK, Kong R, Karim SA, Burton DR, Barouch DH, Nussenzweig MC, Mascola JR, Morris L, Montefiori DC, Korber B, Seaman MS. 2016. Optimal combinations of broadly neutralizing antibodies for prevention and treatment of HIV-1 clade C infection. PLoS Pathog 12:e1005520. https://doi.org/10 .1371/journal.ppat.1005520
35. Sullivan N, Sun Y, Binley J, Lee J, Barbas CF, III, Parren PW, Burton DR, Sodroski J. 1998. Determinants of human immunodeficiency virus type 1 envelope glycoprotein activation by soluble CD4 and monoclonal antibodies. J Virol 72:6332-6338
36. Gardner MR, Fellinger CH, Prasad NR, Zhou AS, Kondur HR, Joshi VR, Quinlan BD, Farzan M. 2016. CD4-Induced antibodies promote association of the HIV-1 envelope glycoprotein with CD4-binding site antibodies. J Virol 90:7822-7832. https://doi.org/10.1128/JVI.00803-16
37. Platt EJ, Bilska M, Kozak SL, Kabat D, Montefiori DC. 2009. Evidence that ecotropic murine leukemia virus contamination in TZM-bl cells does not affect the outcome of neutralizing antibody assays with human immunodeficiency virus type 1. J Virol 83:8289-8292. https://doi.org/10.1128/ JVI.00709-09
38. Platt EJ, Wehrly K, Kuhmann SE, Chesebro B, Kabat D. 1998. Effects of CCR5 and CD4 cell surface concentrations on infections by macrophagetropic isolates of human immunodeficiency virus type 1. J Virol 72: 2855-2864
39. Takeuchi Y, McClure MO, Pizzato M. 2008. Identification of gammaretroviruses constitutively released from cell lines used for human immunodeficiency virus research. J Virol 82:12585-12588. https://doi.org/10 .1128/JVI.01726-08
40. Derdeyn CA, Decker JM, Sfakianos JN, Wu X, O'Brien WA, Ratner L, Kappes JC, Shaw GM, Hunter E. 2000. Sensitivity of human immunodeficiency virus type 1 to the fusion inhibitor T-20 is modulated by coreceptor specificity defined by the V3 loop of gp120. J Virol 74: 8358-8367. https://doi.org/10.1128/JVI.74.18.8358-8367.2000
41. Wei X, Decker JM, Liu H, Zhang Z, Arani RB, Kilby JM, Saag MS, Wu X, Shaw GM, Kappes JC. 2002. Emergence of resistant human immunodeficiency virus type 1 in patients receiving fusion inhibitor (T-20) monotherapy. Antimicrob Agents Chemother 46:1896-1905. https://doi.org/ 10.1128/AAC.46.6.1896-1905.2002
42. Alpert MD, Harvey JD, Lauer WA, Reeves RK, Piatak M, Jr, Carville A, Mansfield KG, Lifson JD, Li W, Desrosiers RC, Johnson RP, Evans DT. 2012. ADCC develops over time during persistent infection with liveattenuated SIV and is associated with complete protection against SIV(mac)251 challenge. PLoS Pathog 8:e1002890. https://doi.org/10 .1371/journal.ppat.1002890
43. Alpert MD, Heyer LN, Williams DE, Harvey JD, Greenough T, Allhorn M, Evans DT. 2012. A novel assay for antibody-dependent cell-mediated cytotoxicity against HIV-1-or SIV-infected cells reveals incomplete overlap with antibodies measured by neutralization and binding assays. J Virol 86:12039-12052. https://doi.org/10.1128/JVI.01650-12
44. Trkola A, Matthews J, Gordon C, Ketas T, Moore JP. 1999. A cell linebased neutralization assay for primary human immunodeficiency virus type 1 isolates that use either the CCR5 or the CXCR4 coreceptor. J Virol 73:8966-8974
45. Lyerly HK, Reed DL, Matthews TJ, Langlois AJ, Ahearne PA, Petteway SR, Jr, Weinhold KJ. 1987. Anti-GP 120 antibodies from HIV seropositive individuals mediate broadly reactive anti-HIV ADCC. AIDS Res Hum Retroviruses 3:409-422. https://doi.org/10.1089/aid.1987.3.409
46. Howell DN, Andreotti PE, Dawson JR, Cresswell P. 1985. Natural killing target antigens as inducers of interferon: studies with an immunoselected, natural killing-resistant human T lymphoblastoid cell line. J Immunol 134:971-976
47. Wu X, Yang ZY, Li Y, Hogerkorp CM, Schief WR, Seaman MS, Zhou T, Schmidt SD, Wu L, Xu L, Longo NS, McKee K, O'Dell S, Louder MK, Wycuff DL, Feng Y, Nason M, Doria-Rose N, Connors M, Kwong PD, Roederer M, Wyatt RT, Nabel GJ, Mascola JR. 2010. Rational design of envelope identifies broadly neutralizing human monoclonal antibodies to HIV-1. Science 329:856-861. https://doi.org/10.1126/science.1187659
48. Barouch DH, Yang ZY, Kong WP, Korioth-Schmitz B, Sumida SM, Truitt DM, Kishko MG, Arthur JC, Miura A, Mascola JR, Letvin NL, Nabel GJ. 2005. A human T-cell leukemia virus type 1 regulatory element enhances the immunogenicity of human immunodeficiency virus type 1 DNA vaccines in mice and nonhuman primates. J Virol 79:8828-8834. https:// doi.org/10.1128/JVI.79.14.8828-8834.2005
49. Farzan M, Vasilieva N, Schnitzler CE, Chung S, Robinson J, Gerard NP, Gerard C, Choe H, Sodroski J. 2000. A tyrosine-sulfated peptide based on the N terminus of CCR5 interacts with a CD4-enhanced epitope of the HIV-1 gp120 envelope glycoprotein and inhibits HIV-1 entry. J Biol Chem 275:33516-33521. https://doi.org/10.1074/jbc.M007228200
50. Choe H, Farzan M, Konkel M, Martin K, Sun Y, Marcon L, Cayabyab M, Berman M, Dorf ME, Gerard N, Gerard C, Sodroski J. 1998. The orphan seven-transmembrane receptor apj supports the entry of primary T-cellline-tropic and dualtropic human immunodeficiency virus type 1. J Virol 72:6113-6118
51. Choe H, Li W, Wright PL, Vasilieva N, Venturi M, Huang CC, Grundner C, Dorfman T, Zwick MB, Wang L, Rosenberg ES, Kwong PD, Burton DR, Robinson JE, Sodroski JG, Farzan M. 2003. Tyrosine sulfation of human antibodies contributes to recognition of the CCR5 binding region of HIV-1 gp120. Cell 114:161-170. https://doi.org/10.1016/S0092-8674(03)00508-7
52. Li M, Gao F, Mascola JR, Stamatatos L, Polonis VR, Koutsoukos M, Voss G, Goepfert P, Gilbert P, Greene KM, Bilska M, Kothe DL, Salazar-Gonzalez JF, Wei X, Decker JM, Hahn BH, Montefiori DC. 2005. Human immunodeficiency virus type 1 env clones from acute and early subtype B infections for standardized assessments of vaccine-elicited neutralizing antibodies. J Virol 79:10108-10125. https://doi.org/10.1128/JVI.79.16 .10108-10125.2005
53. DeSantis MC, Kim JH, Song H, Klasse PJ, Cheng W. 2016. Quantitative correlation between infectivity and Gp120 density on HIV-1 virions revealed by optical trapping virometry. J Biol Chem 291:13088-13097. https://doi.org/10.1074/jbc.M116.729210